Related Experiment Video
Updated: May 31, 2026
12:31
An Ex vivo Model to Study Hormone Action in the Human Breast
Published on: January 8, 2015
Breast tumor characteristics in hormone replacement therapy users.
Jasmina-Ziva Cerne1, Snjezana Frkovic-Grazio, Ksenija Gersak
1Institute of Medical Genetics, Department of Obstetrics and Gynecology, University Medical Centre Ljubljana, Slajmerjeva 3, 1000 Ljubljana, Slovenia.
Pathology Oncology Research : POR
|June 17, 2011
Summary
Hormone replacement therapy (HRT) use in postmenopausal women is linked to breast tumors with a more favorable prognosis. These findings suggest HRT influences tumor differentiation, not just detection.
Area of Science:
- Oncology
- Endocrinology
- Women's Health
Background:
- Hormone replacement therapy (HRT) is commonly used by postmenopausal women.
- The impact of HRT on breast tumor characteristics requires further clarification, considering duration, regimen, and route of administration.
Purpose of the Study:
- To investigate the association between HRT use and breast tumor characteristics in postmenopausal women.
- To determine if HRT duration, regimen, or route influences these tumor characteristics.
Main Methods:
- Retrospective study of 530 postmenopausal women with invasive breast cancer.
- Data collected via postal questionnaire on HRT use and mammographic attendance.
- Logistic regression analysis used to calculate adjusted odds ratios and 95% confidence intervals.
Main Results:
- HRT users exhibited significantly smaller tumors, more ductal histologic types, lower tumor grade, and lower mitotic index compared to non-users.
- Tumor characteristics did not significantly differ by HRT duration, regimen, or route, with a notable exception in mitotic index scores.
- Increased mammographic surveillance in HRT users did not account for the observed favorable tumor characteristics.
Conclusions:
- Breast tumors in HRT users demonstrate a more favorable prognostic profile irrespective of HRT specifics.
- The findings suggest HRT influences preexisting tumors, promoting greater differentiation rather than solely enabling earlier detection.
